Search Results for "BIAL Pharmaceuticals"

18:14 EDT 28th March 2015 | BioPortfolio

Matching Channels

None

Matching News

BIAL’s opicapone significantly improves OFF-time in fluctuating Parkinson’s

Privately-held Portuguese drugmaker BIAL today announced positive results from a Phase III, randomized,…

Former Roche CEO joins BIAL board

Franz Humer to advise Portuguese pharma company

Sunovion Pharmaceuticals Inc. Announces FDA Acceptance for Review of Supplemental New Drug Application for the Use of Aptiom® (eslicarbazepine acetate) as Monotherapy Treatment for Partial-Onset Seizures

Sunovion Pharmaceuticals Inc. (Sunovion) announced today the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for the use...

Sunovion Pharmaceuticals Inc. Submits Supplemental New Drug Application Seeking Approval for the Use of Aptiom® (eslicarbazepine acetate) as Monotherapy Treatment for Partial-Onset Seizures

Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking ap...

Sunovion Pharmaceuticals Inc. Files Patent Infringement Lawsuits Regarding Latuda®

Sumitomo Dainippon Pharma Co., Ltd. (“Sumitomo Dainippon Pharma”) and its U.S. subsidiary, Sunovion Pharmaceuticals Inc. (“Sunovion”), jointly filed patent infringement la...

Questions about life after death remain unanswered

“Life after death is a real phenomenon,” the Metro reports – but the headline is pure hype. Researchers were actually looking at “near-death experiences” – a very different thing. Indeed, ...

PsychoGenics Achieves Another Milestone in Drug Discovery Collaboration with Sunovion

PGI Drug Discovery LLC (PsychoGenics), today announced the achievement of a milestone in its drug discovery and development collaboration with Sunovion Pharmaceuticals Inc. ...

Sunovion Pharmaceuticals Inc. to Divest Xopenex® (levalbuterol HCI) Inhalation Solution (IS) to Akorn, Inc.

Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has signed a definitive agreement (“Agreement”) to sell certain rights to its short-acting bronchodilator Xope...

Matching PubMed Articles

None

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement